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Background: Stereotactic ablative body radiotherapy (SABR) has been proposed as a definitive treatment for
patients with inoperable primary renal cell carcinoma. However, there is little documentation detailing the
radiobiological effects of hypofractionated radiation on healthy renal tissue.
Findings: In this study we describe a methodology for assessment of regional change in renal function in response to
single fraction SABR of 26 Gy. In a patient with a solitary kidney, detailed follow-up of kidney function post-treatment
was determined through 3-dimensional SPECT/CT imaging and 51Cr-EDTA measurements. Based on measurements of
glomerular filtration rate, renal function declined rapidly by 34% at 3 months, plateaued at 43% loss at 12 months, with
minimal further decrease to 49% of baseline by 18 months.
Conclusions: The pattern of renal functional change in 99mTc-DMSA uptake on SPECT/CT imaging correlates with dose
delivered. This study demonstrates a dose effect relationship of SABR with loss of kidney function.
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Introduction
Stereotactic ablative body radiotherapy (SABR) is an
emerging treatment option for inoperable primary renal
cell carcinoma (RCC) in both preclinical [1,2] and early
clinical trials [3]. Local control rates above 90% have been
reported [4-7] and side effects are usually well tolerated
[4,8-10]. It is believed that treatment delivered in a single
fraction may deliver potent dose effects due to radiation-
induced vascular damage, which may prove valuable in
the control of radioresistant tumour strains [11]. This* Correspondence: Shankar.Siva@petermac.org
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unless otherwise stated.effect may have equal consequence in both malignant and
healthy tissue; of particular concern for functional renal
cells where protracted vascular damage due to ionising ra-
diation may have a significant latent period before mani-
festing the effects of injury.
There is limited prospective data of renal impairment
after SABR to the kidney [3]. Dose–response relation-
ships in this context have been thought to be mitigated
by the precision delivery of radiation which may largely
spare substantial amounts of renal parenchyma [12,13].
However, no report to date has reported follow-up with
accurate functional imaging assessment of both global
kidney function using calculated glomerular filtration
rate (GFR) and regional kidney function (using DMSA
SPECT/CT).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ology to identify radiation dose effects to renal tissue for
a patient receiving single-fraction SABR to a patient with
a solitary kidney with primary renal cell carcinoma. Local
dose effects to healthy renal tissue are tracked through
serial functional SPECT/CT imaging and correlated with
radiation dose prescription from treatment planning. This
data represents a detailed report of local radiobiological
changes following this form of hypofractionated therapy
where dose effects are evaluated not just on biochemical
markers (GFR & serum creatinine) but through mea-
sures of tissue function in 3-dimensional nuclear medi-
cine studies.
Methodology
As part of an independent research board approved pro-
spective clinical trial (clinicaltrials.gov ID NCT01676428),
a 42 year old patient was enrolled with an incidentally dis-
covered enlarging primary left renal RCC in a solitary
kidney. This patient had been previously treated with
orchiectomy, retroperitoneal lymph node dissection
and BEP chemotherapy at the age of 19 for a non-
seminomatous germ cell tumour. In 2007, he subse-
quently underwent a right nephrectomy removing two
T1a RCCs. In 2012, the new left solitary kidney mass
was biopsy confirmed as clear cell carcinoma, measured
38 × 34 × 30 mm on CT imaging, and was situated in
the midpole. This patient had renal impairment with an
eGFR of 48 ml/min (creatinine 149 μmol/L). The pa-
tient was otherwise fit, ECOG performance status of 0,
and continued to work full time and exercised daily. A
partial nephrectomy was thought not to be technically
achievable, and a total nephrectomy would have neces-
sitated immediate dialysis. The lesion was located adja-
cent to the renal pelvis in contact with renal vessels
and ureter, and thought not suitable for radiofrequency
ablation. In 2012, he was enrolled as a study participant
and underwent a single fraction of SABR (26 Gy) for
his solitary left kidney RCC. The radiotherapy plan was
generated using a 3D conformal technique with only co-
planar beams in the same axial plane in order to avoid
beams entering and exiting the superior and inferior poles
of the kidney and spare this renal parenchyma (Figure 1).Figure 1 Axial images of renal carcinoma a) on baseline planning CT, b)The dose was prescribed to the 80% isodose, ensuring that
prescription dose encompassed 99% of the target volume.
Radiotherapy was delivered on a Varian Clinac 21iX lin-
ear accelerator (Varian Medical Systems, Palo Alto,
United States) incorporating vacuum immobilisation with
an Elekta BodyFIX device (Elekta Medical Intelligence,
Stockholm, Sweden) as previously published [14,15]. Serial
nuclear medicine assessments were performed.
SPECT imaging & glomerular filtration rate
99mTc-DMSA SPECT/CT images (200 MBq injected ac-
tivity) and GFR by 51Cr-EDTA plasma clearance were re-
corded concurrently at baseline (1 month pre-treatment),
and at 2-weeks, 3-, 12-, & 18-months post SABR. Regional
renal function was quantified based on measured GFR
and total counts in the volume-of-interest comprising the
kidney on SPECT imaging. Each voxel’s contribution to
total renal function [GFR: (ml/min) per ml tissue] was
then calculated based on that scaling factor. The quanti-
fied voxel values were compared between baseline and
follow-up scans in order to calculate change in local renal
function according to prescribed isodose region from the
radiotherapy treatment plan.
SPECT images were coregistered to the pre-therapy
planning CT and dose prescription image sets. Fused
SPECT/CTs were aligned by deformable registration of
anatomical, CT volumes with the MIM software package
(version 6.1, MIM Software Inc, Cleveland OH, USA).
Planning structures were utilised for segmentation of
healthy renal tissue [Kidney minus Internal Target Vol-
ume (ITV)] [16]. Healthy renal tissue was then differenti-
ated based on radiation isodose zone in 1 Gy increments
to record mean counts and volume per zone and identify
a dose/response relationship.
Results
At 18 months post treatment, the patient’s disease is con-
trolled after single-fraction ablative radiotherapy. The posi-
tioning of treatment fields within the axial plane permitted
the sparing of substantial volumes of renal tissue at the su-
perior and inferior limits of the kidney volume.
99mTc-DMSA SPECT/CT scans indicate that renal cor-
tical function is spared to regions with prescribed radiationpre-therapy T2-weighted MRI, & c) T2 MRI at 18 months post-SABR.
Figure 2 Serial baseline & post-treatment renal perfusion scans: coronal slices from serial 99mTc-DMSA SPECT scans at a) baseline,
b) 2 weeks, c) 3 months, d) 12 Months, & e) 18 months.
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the prescription dose). In this patient, 60% of tissue was
spared appreciable deterioration in regional function, in
line with the 13 Gy isodose volume as seen in Figure 2. A
modest decline in 99mTc-DMSA uptake is observed at
2-weeks & 3 months post-therapy for high-dose regions. It
is apparent from late follow up scans, however, that evi-
dence of radiation induced injury may be delayed for up to
a year (Figure 3). Ongoing evolution of dose dependent
loss in renal perfusion is demonstrated at 12 months after
treatment. At 12 & 18 months the pattern of tracer uptake
closely matches the spared dose zones from treatment
planning. Minimal decline in perfusion and GFR were ob-
served beyond one year and at a rate that is consistent with
the trajectory of progressive chronic kidney disease as pre-
viously described by Demirjian et al. [17], (Figure 3b).
From a clinical perspective, the patient continues to
work full-time, has an ECOG performance status of 0,
and continues to lead a productive lifestyle. He is asymp-
tomatic from his decline in renal function with no sig-
nificant clinical toxicity.Figure 3 Temporal renal perfusion change according to delivered rad
the treatment follow-up period (b).Discussion
In this study we find both imaging and biochemical data
suggest that dose effects to healthy renal tissue continue
to evolve beyond three months after SABR but may sta-
bilise at approximately one year post treatment. In spite
of this patient’s previous nephrectomy, platinum-based
chemotherapy, and retroperitoneal surgery which con-
tributed to pre-treatment renal dysfunction, the delivery
of hypofractionated ablative radiotherapy to the centrally-
located tumour in remaining kidney has spared a suffi-
cient volume of functional tissue for the patient to remain
free from dialysis.
It is evident that functional nuclear medicine imaging
can be informative for assessing normal tissue effects in
ablative radiotherapy for renal cell carcinoma. In this in-
stance, DMSA perfusion has been utilised as a surrogate
for local renal function. 3-dimensional 99mTc-DMSA
SPECT/CT images have indicated that function loss occurs
primarily to regions receiving an absorbed dose >13 Gy
which corresponds to 50% of the prescription dose and
higher in this instance. Whether functional loss within theiation dose (a) and measured glomerular filtration rate during
Jackson et al. Radiation Oncology 2014, 9:253 Page 4 of 4
http://www.ro-journal.com/content/9/1/253intermediate to high dose region is clinically consist-
ent across a broader population of patients is yet to be
confirmed.
Conclusion
Single fraction SABR shows promise as viable treatment
option for inoperable primary RCC with significant spa-
ring of renal parenchyma in a patient treated with a soli-
tary kidney, although longer-term follow-up is awaited.
For the patient reported in this case study, a single-
fraction threshold of <13 Gy results in preserved local
renal function, with a significant dose/effect relationship
at intermediate to high dose ranges (13–25 Gy). This
finding requires further validation from multiple patients
to confirm the radiation tolerance of renal parenchyma.
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